Study on radiomics to predict the aggressiveness of multiple primary invasive lung adenocarcinomas
Qinling Sun(Kunming Medical University), Lianhua Ye(Kunming Medical University), Zhi-qiang Ouyang(Kunming Medical University), Yichen Yang(Kunming Medical University), Biying Wang(Kunming Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Yantao Yang(Kunming Medical University), Qiubo Huang, Guangqiang Zhao(Kunming Medical University), Chengde Liao(Kunming Medical University)
Cited by 0
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Resting-State Functional MRI: Everything That Nonexperts Have Always Wanted to Know
|American Journal of Neuroradiology|2018|569
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508